Clinical trials: Spasticity With Multiple Sclerosis
Multiple Sclerosis (MS)
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
This trial is being conducted to demonstrate the efficacy of nabiximols, compared with placebo, when added to standard of care, in the treatment of muscle spasms associated with multiple sclerosis (MS).
- Trial name
- RELEASE MSS3 (NCT04203498)
- Testing
- Nabiximols
- Where
- 37 sites in United States, Czechia and 3 more
- Volunteers
- 139 people
- Sponsor
- Jazz Pharmaceuticals
Spasticity With Multiple Sclerosis
Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
This study will be conducted to evaluate the effect of multiple doses of nabiximols compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Lower Limb Muscle Tone-6 [LLMT-6]) in…
- Trial name
- RELEASE MSS5 (NCT04984278)
- Testing
- Nabiximols
- Where
- 30 sites in United States, Czechia and 3 more
- Volunteers
- 56 people
- Sponsor
- Jazz Pharmaceuticals
Spasticity, Multiple Sclerosis
Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis
The purpose of this study is to evaluate the maintenance of effect after long-term treatment with Sativex® in subjects with symptoms of spasticity due to Multiple Sclerosis (MS) who have been receiving long-term benefit from…
- Trial name
- NCT00702468
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- Jazz Pharmaceuticals
Spasticity in Participants With Multiple Sclerosis
Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
This study will be conducted to evaluate the effect of multiple doses of nabiximols as adjunctive therapy compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Modified Ashworth Scale…
- Trial name
- RELEASE MSS1 (NCT04657666)
- Testing
- Nabiximols
- Where
- 16 sites in Czechia, Poland
- Volunteers
- 68 people
- Sponsor
- Jazz Pharmaceuticals
Spasticity, Multiple Sclerosis
A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.
The purpose of this study is to evaluate the efficacy, safety and tolerability of Sativex® in subjects diagnosed with MS and spasticity.
- Trial name
- NCT00711646
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 189 people
- Sponsor
- Jazz Pharmaceuticals
Spasticity
Study of SPARC1103 in Subjects With Spasticity
Study of SPARC1103 in subjects with spasticity
- Trial name
- NCT02027025
- Testing
- SPARC1103 low dose, SPARC1103 high dose
- Where
- 23 sites in United States, Russia and 1 more
- Volunteers
- 142 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Multiple Sclerosis, Spasticity
A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients
A study to compare the change in cognitive performance and psychological status of patients with spasticity due to Multiple Sclerosis when treated with Sativex or placebo, added to existing anti-spasticity therapy over a period…
- Trial name
- NCT01964547
- Testing
- Sativex
- Where
- Czechia
- Volunteers
- 121 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis
Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis
Multiple Sclerosis (MS) is a disorder of the body's immune system that affects the Central Nervous System (CNS). Normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain…
- Trial name
- NCT00053417
- Testing
- 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP), 15 mg fampridine-SR (4-aminopyridine, 4-AP), 20 mg fampridine-SR (4-aminopyridine, 4-AP)
- Where
- 25 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- Acorda Therapeutics
Multiple Sclerosis
Evaluation of a Spasticity Management Program for People With Multiple Sclerosis
This study will examine the impacts of two different methods of managing MS-related spasticity of the lower limbs. Both interventions will be presented via video teleconference in group classes consisting of exercises to reduce…
- Trial name
- STC (NCT03166930)
- Testing
- Spasticity Take Control, Stretching for People with MS: An Illustrated Manual
- Where
- United States
- Volunteers
- 232 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis, Spasticity
A Long-term Safety Extension Study of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis
An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02 treatment in multiple sclerosis.
- Trial name
- NCT01610687
- Testing
- GW-1000-02
- Where
- United Kingdom
- Volunteers
- 137 people
- Sponsor
- Jazz Pharmaceuticals
Spasticity, Multiple Sclerosis
A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)
The purpose of this study is to determine whether Sativex® versus Placebo is effective in the relief of symptoms of spasticity in subjects with multiple sclerosis, who have been identified as having a capacity to respond to…
- Trial name
- NCT00681538
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 572 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Spasticity, Muscle
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
Multiple Sclerosis (MS) is an acquired inflammatory demyelinating disease of the central nervous system (CNS) that is regarded as the foremost cause of non-traumatic neurologic disability in adults in North America.
- Trial name
- OS440-3004 (NCT03290131)
- Testing
- Arbaclofen
- Where
- 30 sites in Belarus, Bosnia and Herzegovina and 5 more
- Volunteers
- 536 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Multiple Sclerosis
Impact of Direct Current Electrical Stimulation on Spasticity Levels and Functional Muscle Use in MS
In an individual with MS the central nervous system (CNS) is over-protective and causes the threshold for stretch reflex and muscle tightness to be set lower than normal.
- Trial name
- NCT04942938
- Testing
- Neubie
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- CommonSpirit Health
Multiple Sclerosis
A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis
The purpose of this study was to assess the efficacy of Sativex in relieving symptoms of spasticity in multiple sclerosis
- Trial name
- NCT01599234
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 337 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis, Spasticity, Muscle
A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
Spasticity is a common complication in MS and occurs in up to 84% of patients. The main sign of spasticity is resistance to passive limb movement characterized by increased resistance to stretching, clonus, and exaggerated deep…
- Trial name
- OS440-3005 (NCT03319732)
- Testing
- Arbaclofen
- Where
- United States
- Volunteers
- 323 people
- Sponsor
- RVL Pharmaceuticals, Inc.